{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:07:34Z","timestamp":1793696854291,"version":"4.5.1"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic obstructive pulmonary disease (COPD) is a persistent, often progressive lung disease with a highly heterogeneous patient population. Its management has traditionally relied on clinical symptoms and pulmonary function tests. However, this approach has limitations due to a poor alignment between the clinical symptoms and underlying individual pathological mechanisms, as well as a heavy reliance on chest imaging, restricting its wide application in resource-limited settings. This review aimed to bridge the gap between clinical presentation and underlying mechanisms by systematically mapping cellular inflammatory phenotypes to targeted therapies. We critically examined the evolution from clinical to cellular phenotyping, highlighting the potential of mechanistic, cell-based classifications to improve COPD management. The proposed cellular phenotype classification\u2014neutrophilic (&amp;gt;60% sputum neutrophils), eosinophilic (\u22653% eosinophils), lymphocytic, macrophage, and mixed granulocytic\u2014has been validated in multinational cohorts and provides a framework for precision interventions: inhibiting the CXCR1\/2 pathway or neutrophil elastase for the neutrophilic phenotype, and anti-interleukin-5\/interleukin-13 biologics or Th2 blockade for the eosinophilic phenotype. We propose a four-tiered diagnostic pathway comprising biomarker screening, multi-omics validation, consensus assignment, and dynamic therapy escalation. This approach shifts COPD management from symptom control to pathogenesis modification. However, substantial challenges remain in translating cellular phenotypes into routine practice, warranting further research.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1846920","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:41:51Z","timestamp":1779338511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From clinical phenotypes to cellular mechanisms: a precision medicine framework for COPD"],"prefix":"10.3389","volume":"17","author":[{"given":"Jianjun","family":"Wu","sequence":"first","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Wang","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benzhang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hantao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Chen","sequence":"additional","affiliation":[{"name":"Respiratory Department, The Third Affiliated Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01273-9","article-title":"Towards the elimination of chronic obstructive pulmonary disease: a Lancet commission","volume":"400","author":"Stolz","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12931-025-03356-w","article-title":"Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits","volume":"26","author":"Xie","year":"2025","journal-title":"Respir Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00422-2024","article-title":"Peeping at COPD through the keyhole: time to broaden the view to the complexity of the disease by the heterogeneity of symptoms","volume":"10","author":"Finamore","year":"2024","journal-title":"ERJ Open Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.15.04152","article-title":"Prognostic risk profiling in COPD using Global Initiative for Chronic Obstructive Lung Disease 2023 ABE and comorbidity assessment: evidence from a register-based COPD cohort","volume":"15","author":"Lin","year":"2025","journal-title":"J Glob Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202102-0293RR","article-title":"Phenotypic heterogeneity in chronic obstructive pulmonary disease","volume":"205","author":"Kaul","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"210118","DOI":"10.1183\/20734735.0118-2021","article-title":"The use of treatable traits to address COPD complexity and heterogeneity and to inform the care","volume":"17","author":"Duszyk","year":"2021","journal-title":"Breathe Sheff"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2017.1303041","article-title":"Phenotyping before starting treatment in COPD","volume":"14","author":"Siafakas","year":"2017","journal-title":"COPD"},{"key":"B8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1164\/rccm.200912-1843CC","article-title":"Chronic obstructive pulmonary disease phenotypes: the future of COPD","volume":"182","author":"Han","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.22.07927-7","article-title":"Pathogenesis of COPD at the cellular and molecular level","volume":"113","author":"DI Stefano","year":"2022","journal-title":"Minerva Med"},{"key":"B12","unstructured":"2026 GOLD report and pocket guide"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2021.08.002","article-title":"Spanish COPD Guideline (GesEPOC) update: comorbidities, self-management and palliative care","volume":"58","author":"Lopez-Campos","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2020.12.010","article-title":"Deconstructing phenotypes in COPD: an analysis of the TRACE cohort","volume":"58","author":"Carrasco Hern\u00e1ndez","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2021.05.011","article-title":"Spanish COPD Guidelines (GesEPOC) 2021 update diagnosis and treatment of COPD exacerbation syndrome","volume":"58","author":"Soler-Catalu\u00f1a","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"190064","DOI":"10.1183\/16000617.0064-2019","article-title":"Sleep in chronic respiratory disease: COPD and hypoventilation disorders","volume":"28","author":"McNicholas","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.01.001","article-title":"Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD)","volume":"107","author":"Izquierdo-Alonso","year":"2013","journal-title":"Respir Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12890-019-0935-2","article-title":"Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study","volume":"19","author":"Nicola","year":"2019","journal-title":"BMC Pulm Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12931-020-01512-y","article-title":"Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.11.1521831","article-title":"Roflumilast for COPD","volume":"46","author":"Izquierdo","year":"2010","journal-title":"Drugs Today Barc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57111261","article-title":"Emphysema-predominant COPD had a greater 5-year mortality and a worse annual decline in lung function than airway obstruction-predominant COPD or asthma at initial same degree of airflow obstruction","volume":"57","author":"Lin","year":"2021","journal-title":"Med Kaunas"},{"key":"B22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1164\/rccm.202303-0507LE","article-title":"Spatial transcriptomics resolve an emphysema-specific lymphoid follicle B cell signature in chronic obstructive pulmonary disease","volume":"209","author":"Rojas-Quintero","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14799","article-title":"COPD is associated with increased cardiovascular disease risk independent of phenotype","volume":"29","author":"Cobb","year":"2024","journal-title":"Respirology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1702146","DOI":"10.1183\/13993003.02146-2017","article-title":"Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype","volume":"51","author":"Celli","year":"2018","journal-title":"Eur Respir J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112147-20240113-00029","article-title":"Current status of interventional bronchoscopy in chronic obstructive pulmonary disease","volume":"47","author":"Liu","year":"","journal-title":"Chin J Tuberculosis Respir Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030287","article-title":"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","volume":"348","author":"Fishman","year":"2003","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2020.056","article-title":"Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society","volume":"164","author":"Zatloukal","year":"2020","journal-title":"BioMed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00004-2024","article-title":"COPD: systemic proteomic profiles in frequent and infrequent exacerbators","volume":"10","author":"Enr\u00edquez-Rodr\u00edguez","year":"2024","journal-title":"ERJ Open Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00595-2023","article-title":"Sputum microbiome \u03b1-diversity is a key feature of the COPD frequent exacerbator phenotype","volume":"10","author":"Pragman","year":"2024","journal-title":"ERJ Open Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/bmb\/ldaa043","article-title":"The different phenotypes of COPD","volume":"137","author":"Yousuf","year":"2021","journal-title":"Br Med Bull"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S440252","article-title":"The dosing strategy to improve adherence to roflumilast in treatment for chronic obstructive lung disease: a systemic review and meta-analysis","volume":"19","author":"Lee","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.06.004","article-title":"Asthma-COPD coexistence","volume":"154","author":"Barnes","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1271342","article-title":"Modulating asthma-COPD overlap responses with IL-17 inhibition","volume":"14","author":"do N. Camargo","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.09.036","article-title":"Asthma-COPD overlap: What are the important questions","volume":"161","author":"Leung","year":"2022","journal-title":"Chest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jaip.2020.09.066","article-title":"A randomized, noninferiority trial comparing ICS + LABA with ICS + LABA + LAMA in asthma-COPD overlap (ACO) treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study","volume":"9","author":"Park","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073365","article-title":"Unraveling the immune landscape of chronic obstructive pulmonary disease: insights into inflammatory cell subtypes, pathogenesis, and treatment strategies","volume":"26","author":"Lan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.006650","article-title":"Inflammatory features of nasal mucosa in smokers with and without COPD","volume":"59","author":"Vachier","year":"2004","journal-title":"Thorax"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001454","article-title":"Characteristics of inflammatory phenotypes in patients with chronic obstructive pulmonary disease: a cross-sectional study","volume":"10","author":"Wen","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S252097","article-title":"Th1\/Th17 cytokine profiles are associated with disease severity and exacerbation frequency in COPD patients","volume":"15","author":"Yu","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079611","article-title":"Systemic CD4+ and CD8+ T-cell cytokine profiles correlate with GOLD stage in stable COPD","volume":"40","author":"Paats","year":"2012","journal-title":"Eur Respir J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201305-123AW","article-title":"Altered macrophage function in chronic obstructive pulmonary disease","author":"Hiemstra","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"B45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.7150\/ijms.100160","article-title":"Advances on the role of lung macrophages in the pathogenesis of chronic obstructive pulmonary disease in the era of single-cell genomics","volume":"22","author":"Li","year":"2025","journal-title":"Int J Med Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12890-020-1086-1","article-title":"Blood cell for the differentiation of airway inflammatory phenotypes in COPD exacerbations","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Pulm Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11030464","article-title":"The emerging role of macrophages in chronic obstructive pulmonary disease: the potential impact of oxidative stress and extracellular vesicle on macrophage polarization and function","volume":"11","author":"Finicelli","year":"2022","journal-title":"Antioxidants Bsl"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2023.108997","article-title":"A multiscale hybrid model for exploring the effect of Resolvin D1 on macrophage polarization during acute inflammation","volume":"359","author":"Uleman","year":"2023","journal-title":"Math Biosci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.15586\/aei.v52i5.1135","article-title":"Shengmai powder regulates alveolar macrophage PPAR-\u03b3 and improves the chronic inflammatory state of chronic obstructive pulmonary disease","volume":"52","author":"Liu","year":"2024","journal-title":"Allergol Immunopathol Madr"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur Respir J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2285924","article-title":"Prediction value of neutrophil and eosinophil count at risk of COPD exacerbation","volume":"55","author":"Chen","year":"2023","journal-title":"Ann Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1042\/CS20255452","article-title":"COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets","volume":"139","author":"Fricker","year":"2025","journal-title":"Clin Sci Lond"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S176122","article-title":"Role of inflammatory cells in airway remodeling in COPD","volume":"13","author":"Wang","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.113647","article-title":"Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD","volume":"64","author":"Di Stefano","year":"2009","journal-title":"Thorax"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106449","article-title":"Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration","volume":"83","author":"Guan","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081065","article-title":"Neutrophil elastase and chronic lung disease","volume":"11","author":"Voynow","year":"2021","journal-title":"Biomolecules"},{"key":"B57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/15412555.2018.1476475","article-title":"Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease","volume":"15","author":"Butler","year":"2018","journal-title":"COPD"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627922","article-title":"MCPIP-1 restricts inflammation via promoting apoptosis of neutrophils","volume":"12","author":"Dobosz","year":"2021","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2006.1.2.161","article-title":"Apoptotic mechanisms in the pathogenesis of COPD","volume":"1","author":"Plataki","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211039769","article-title":"Inhibition of LC3-associated phagocytosis in COPD and in response to cigarette smoke","volume":"15","author":"Asare","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000868","article-title":"NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitate HBV-related acute-on-chronic liver failure","volume":"81","author":"Zhao","year":"2025","journal-title":"Hepatology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S419056","article-title":"Novel anti-inflammatory approaches to COPD","volume":"18","author":"Cazzola","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.4.1240","article-title":"Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4","volume":"123","author":"Beeh","year":"2003","journal-title":"Chest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-7-65","article-title":"Delayed apoptosis by neutrophils from COPD patients is associated with altered Bak, Bcl-xl, and Mcl-1 mRNA expression","volume":"7","author":"Zhang","year":"2012","journal-title":"Diagn Pathol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"220144","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur Respir Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: A biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2500194","DOI":"10.1183\/13993003.00194-2025","article-title":"Eosinophils in COPD type 2 inflammation: hope or hype","volume":"65","author":"Polverino","year":"2025","journal-title":"Eur Respir J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2401875","DOI":"10.1183\/13993003.01875-2024","article-title":"Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response","volume":"65","author":"Leung","year":"2025","journal-title":"Eur Respir J"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02188-8","article-title":"Chronic obstructive pulmonary disease (COPD): developments in pharmacological treatments","volume":"85","author":"Singh","year":"2025","journal-title":"Drugs"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2024.05.011","article-title":"Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins","volume":"125","author":"Varricchi","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00802-2024","article-title":"Effect of benralizumab treatment on the airway microbiome in COPD","volume":"11","author":"Haldar","year":"2025","journal-title":"ERJ Open Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00044-X","article-title":"Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial","volume":"31","author":"Christenson","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219620","article-title":"Budesonide\/formoterol maintenance and reliever therapy versus fluticasone\/salmeterol fixed-dose treatment in patients with COPD","volume":"78","author":"Muiser","year":"2023","journal-title":"Thorax"},{"key":"B77","doi-asserted-by":"publisher","first-page":"106301","DOI":"10.1016\/j.ejim.2025.04.008","article-title":"Short term variability of peripheral blood eosinophil count in individuals with stable COPD","volume":"139","author":"Candia","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S2213-2600(24)00381-3","article-title":"Evaluating tezepelumab for COPD: a missed target or unmet potential","volume":"13","author":"Cazzola","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-024-03940-9","article-title":"Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option","volume":"15","author":"Lai","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112765","article-title":"Phenotypes of regulatory T cells in different stages of COPD","volume":"140","author":"Alves","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2300589","DOI":"10.1183\/13993003.00589-2023","article-title":"The impact of the immune system on lung injury and regeneration in COPD","volume":"62","author":"Kapellos","year":"2023","journal-title":"Eur Respir J"},{"key":"B82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.1.71","article-title":"Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD","volume":"125","author":"Chrysofakis","year":"2004","journal-title":"Chest"},{"key":"B84","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2003.08.007","article-title":"Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease","volume":"98","author":"Tzanakis","year":"2004","journal-title":"Respir Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071538","article-title":"Experimental insights on the use of secukinumab and magnolol in acute respiratory diseases in mice","volume":"12","author":"Vicovan","year":"2024","journal-title":"Biomedicines"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111849","article-title":"Interleukin-2\/anti-interleukin-2 complex attenuates inflammation in a mouse COPD model by expanding CD4+ CD25+ Foxp3+ regulatory T cells","volume":"131","author":"Duan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S520795","article-title":"The role and clinical significance of vitamin D in chronic obstructive pulmonary disease","volume":"20","author":"Sun","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13417","article-title":"The effect and associated mechanism of action of phosphodiesterase 4 (PDE4) inhibitor on CD4+ lymphocyte proliferation","volume":"48","author":"Kim","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"240053","DOI":"10.1183\/16000617.0053-2024","article-title":"Macrophages and the microbiome in chronic obstructive pulmonary disease","volume":"33","author":"Sandhu","year":"2024","journal-title":"Eur Respir Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115631","article-title":"Macrophage polarization and functions in pathogenesis of chronic obstructive pulmonary disease","volume":"25","author":"Kim","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107035","article-title":"The role of lung macrophages in chronic obstructive pulmonary disease","volume":"205","author":"Wu","year":"2022","journal-title":"Respir Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-020-00345-x","article-title":"Progress in the mechanism and targeted drug therapy for COPD","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Tgt Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020582","article-title":"Lung macrophage phenotypes and functional responses: role in the pathogenesis of COPD","volume":"19","author":"Yamasaki","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1042\/CS20191202","article-title":"Effects of corticosteroids on COPD lung macrophage phenotype and function","volume":"134","author":"Higham","year":"2020","journal-title":"Clin Sci Lond"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163139","article-title":"Differential effects of p38, MAPK, PI3K or rho kinase inhibitors on bacterial phagocytosis and efferocytosis by macrophages in COPD","volume":"11","author":"Bewley","year":"2016","journal-title":"PloS One"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1038\/s41598-022-09241-6","article-title":"The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro","volume":"12","author":"Milara","year":"2022","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/proteomes12030023","article-title":"The current molecular and cellular landscape of chronic obstructive pulmonary disease (COPD): a review of therapies and efforts towards personalized treatment","volume":"12","author":"Farrell","year":"2024","journal-title":"Proteomes"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1846920\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:42:07Z","timestamp":1779338527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1846920\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":101,"alternative-id":["10.3389\/fimmu.2026.1846920"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1846920","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1846920"}}